Nicotine Pouches May Be the Lowest-Risk Alternative Yet—Here’s What the Science Says 

At a time when the conversation around nicotine is often driven more by fear than facts, new research is once again pointing in a different direction—one grounded in science, not speculation. 

A major new review from leading researcher Dr. Konstantinos Farsalinos, published in Internal and Emergency Medicine, suggests that nicotine pouches could represent the lowest-risk alternative to smoking currently available. 

And the implications for harm reduction are hard to ignore. 

👉 Read the full study here: https://link.springer.com/article/10.1007/s11739-026-04278-1 

A Clear Position on the Risk Spectrum 

For years, public health experts have talked about the “continuum of risk”—the idea that not all nicotine products are created equal. 

Combustible cigarettes sit firmly at the top of that scale. 

According to this new review, tobacco-free nicotine pouches sit at the very bottom. 

The reason comes down to chemistry. 

Dr. Farsalinos found that harmful chemicals commonly associated with smoking—like tobacco-specific nitrosamines—are either undetectable or present at negligible levels in nicotine pouches, especially when compared to cigarettes and even traditional smokeless products like snus. 

In practical terms, that means dramatically lower exposure to the toxicants responsible for smoking-related disease. 

Comparable to Quitting Smoking Entirely 

One of the most compelling findings in the review is this: 

Smokers who switch to nicotine pouches experience reductions in toxicant exposure comparable to quitting smoking altogether. 

That’s a significant statement—and one that aligns with what we’ve seen across other harm reduction products. 

At the same time, nicotine pouches still deliver enough nicotine to help manage cravings, making them a viable option for adult smokers who struggle to quit using traditional methods. 

Because the reality is simple: 
Nicotine may be addictive—but it’s the combustion in cigarettes that causes the overwhelming majority of harm. 

The Swedish Model: Proof in Practice 

The review also draws on decades of real-world data from Sweden, where widespread use of snus has contributed to some of the lowest smoking rates in the world. 

Importantly: 

• Snus has not been linked to lung cancer 
• It shows no significant association with major cardiovascular disease 

This creates what researchers call a “bridging” argument—supporting the safety profile of modern, tobacco-free nicotine pouches based on similar exposure patterns. 

And the results speak for themselves. 

Sweden is on the verge of becoming one of the first truly smoke-free countries. 

Not a Gateway—But a Way Out 

Another key takeaway from the review: 
There is little evidence that nicotine pouches act as a gateway to smoking. 

Instead, they appear to function exactly as intended—as an off-ramp for adult smokers. 

Dr. Delon Human, leader of Smoke Free Sweden and former Secretary-General of the World Medical Association, put it plainly: 

“Nicotine pouches are proving to be one of the safest alternatives ever developed for smokers who can’t or won’t quit.” 

That distinction matters. 

Because harm reduction isn’t about perfection—it’s about meeting people where they are and giving them safer options. 

The Policy Disconnect 

Despite growing evidence, many regulators continue to treat all nicotine products as if they carry the same level of risk. 

But studies like this make one thing increasingly clear: 

When lower-risk alternatives are restricted, the most dangerous product—cigarettes—wins by default. 

Countries like Sweden have taken a different approach—embracing regulated alternatives and giving smokers real choices. 

The result? Fewer smokers. Fewer smoking-related deaths. Better public health outcomes. 

The Bottom Line 

This new review reinforces a critical truth: 

• Not all nicotine use is the same 
• Combustion drives harm—not nicotine itself 
• Safer alternatives can and do save lives 

Nicotine pouches aren’t a silver bullet—but for millions of adult smokers, they may be one of the most effective and lowest-risk tools available today. 

The question isn’t whether these products have a role in harm reduction. 

It’s whether policy will catch up to the science.